Timber Pharma efficiently targeting niche dermatology markets - Wainwright

Trex Wind-Down

31/03/2022 14:54

** Shares of Timber Pharmaceuticals INC  TMBR.K , a
dermatologic disease focused drugmaker, rise 4.5% in early trade
to $0.41 - their highest this year 
    ** Brokerage H.C. Wainwright starts coverage with "buy" and
PT of $2, representing a near five-fold rise from current levels
    ** "Timber is pursuing a cost-effective, capital-efficient
drug development strategy by focusing on niche markets within
the dermatology arena" - Wainwright  
    ** Says Timber may be able to self-commercialize its drug
candidates with a small, specialty sales force that focuses
solely on high-value prescribers
    ** "Timber's focus on well-known, robustly characterized
active pharmaceutical ingredients should avoid many of the risks
associated with new drug development" - brokerage
    ** Stock up ~7% YTD including session gains 

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))